Osimertinib: A Benchmark in Targeted Therapy Osimertinib The European Commission has granted approval for the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who harbor EGFR exon…
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous (SC) formulation of Sarclisa, administered through an on-body delivery system…
The Role of G6PD Testing in Malaria Treatment On December 18, 2024, the World Health Organization (WHO) achieved a groundbreaking milestone by prequalifying the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. This move aims to enhance the safe delivery…
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial intelligence (AI), and a continued focus on late-stage assets and…
Biopharma Leaders M&A Didn’t Deliver as Expected in 2024: Biopharma Turns to JPMorgan Healthcare Conference for Optimism Biopharma Leaders the much-anticipated mergers and acquisitions (M&A) wave that the biopharma industry hoped would materialize in 2024 did not arrive as expected,…
Propranolol Reduces Tremors in Parkinson’s Disease: Insights into the Role of Stress and the Brain Parkinson’s disease is a progressive neurodegenerative disorder that affects movement, often leading to symptoms such as tremors, stiffness, and slowness of movement. Tremors, in particular,…
The World Health Organization (WHO) has expressed deep dismay following the raid on Kamal Adwan Hospital, which has rendered the last major health facility in North Gaza non-operational. This attack underscores the systematic dismantling of the region’s health infrastructure, coupled…
Aetna , a CVS Health® company , has enhanced the functionality of its Aetna Health℠ app to offer Spanish language support for all eligible health plan members, regardless of their coverage type or location. This update is designed to improve…
Merck known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg mg)] in adults with HIV-1 infection…
Hansoh Pharma has granted MSD (the tradename of Merck & Co., Inc., Rahway, N.J., USA) an exclusive global license for HS-10535, its investigational oral small molecule GLP-1 receptor agonist. This collaboration represents a significant step in advancing therapies for cardiometabolic…
Eli Lilly and Company announced today that China’s National Medical Products Administration (NMPA) has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Lilly’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease. This includes individuals…
Merck known as MSD outside of the United States and Canada, has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab was being evaluated in combination with pembrolizumab (KEYTRUDA®) in the…